Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) – Drugs In Development, 2023’, provides an overview of the Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)
- The report reviews pipeline therapeutics for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) therapeutics and enlists all their major and minor projects
- The report assesses Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
4C Biomed IncAadi Bioscience Inc
Agenus Inc
Archivel Farma SL
Astellas Pharma Inc
AstraZeneca Plc
Athna Biotech Inc
ATONCO SAS
Aura Biosciences Inc
Aurora Oncology Inc
Autonomous University of Barcelona
BacoCure
BeiGene Ltd
Bioven Group
Bristol-Myers Squibb Co
CG Oncology Inc
Chengdu Keen Biotechnology Co Ltd
CHU de Quebec Universite Laval Research Center
CicloMed LLC
Cugene Inc
Daiichi Sankyo Co Ltd
Emtora Biosciences
enGene Holdings Inc
F. Hoffmann-La Roche Ltd
Farmabrasilis
Ferring International Center SA
Fidia farmaceutici SpA
H. Lee Moffitt Cancer Center and Research Institute Hospital Inc
Hamlet Pharma AB
Huons Co Ltd
ImmunityBio Inc
Imunon Inc
Incyte Corp
InnoBM Pharmaceuticals Co Ltd
Intas Pharmaceuticals Ltd
IO Biotech Inc
Istari Oncology Inc
Jiangsu Hengrui Medicine Co Ltd
Jiangsu Yahong Meditech Co Ltd
Johnson & Johnson
Kissei Pharmaceutical Co Ltd
Lausanne University Hospital
Lepu Biopharma Co Ltd
Lindis Biotech GmbH
LintonPharm Co Ltd
Lipac Oncology LLC
Manhattan Biosolutions Inc
Merck & Co Inc
Merck KGaA
Moderna Inc
Nanobots Therapeutics
Nanology LLC
OncoSTING LLC
Pfizer Inc
Prokarium Ltd
Ractigen Therapeutics Inc
RemeGen Co Ltd
Rockefeller University
Shionogi & Co Ltd
Simcere Pharmaceutical Group Ltd
Spectrum Pharmaceuticals Inc
Sunho (China) Biopharmaceutical Co Ltd
SURGE Therapeutics Inc
Theralase Technologies Inc
Tollys SAS
UroGen Pharma Ltd
Vaxiion Therapeutics Inc
Venenum Biodesign LLC
Wuhan Binhui Biopharmaceutical Co Ltd
Zhuhai Beihai Biotech Co Ltd